BR9910830A - Vacinas de ácido nucléico para prevenção de infecção flavivìrus - Google Patents

Vacinas de ácido nucléico para prevenção de infecção flavivìrus

Info

Publication number
BR9910830A
BR9910830A BR9910830-5A BR9910830A BR9910830A BR 9910830 A BR9910830 A BR 9910830A BR 9910830 A BR9910830 A BR 9910830A BR 9910830 A BR9910830 A BR 9910830A
Authority
BR
Brazil
Prior art keywords
nucleic acid
encompasses
individual
infection
protein antigens
Prior art date
Application number
BR9910830-5A
Other languages
English (en)
Inventor
Gwong-Jen J Chang
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of BR9910830A publication Critical patent/BR9910830A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1081—Togaviridae, e.g. flavivirus, rubella virus, hog cholera virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/08—RNA viruses
    • G01N2333/18—Togaviridae; Flaviviridae
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)

Abstract

Patente de Invenção para <B>"VACINAS DE áCIDO NUCLéICO PARA PREVENçãO DE INFECçãO FLAVIVìRUS"<D> A invenção abrange moléculas de ácido nucléico contendo unidades de transcrição as quais codificam os antígenos de proteína flavivírus M e E. Os flavivírus incluem vírus da encefalite Japonesa, dengue, vírus da febre amarela e vírus da encefalite St. Louis. O ácido nucléico funciona para prover os antígenos de proteína M e E quando o ácido nucléico reside em uma célula hospedeira apropriada, especialmente quando a célula hospedeira é a célula de um indivíduo. A invenção também abrange uma vacina cujo agente ativo é o ácido nucléico. A invenção adicionalmente abrange as células hospedeiras cultivadas quando elas contêm dentro delas as moléculas de ácido nucléico contendo unidades de transcrição. A invenção em adição abrange um método de imunização de um indivíduo contra a infecção por flavivírus, por administração ao indivíduo uma quantidade efetiva de uma vacina contendo a molécula de ácido nucléico contendo a unidade de transcrição da invenção.
BR9910830-5A 1998-06-04 1999-06-03 Vacinas de ácido nucléico para prevenção de infecção flavivìrus BR9910830A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8790898P 1998-06-04 1998-06-04
PCT/US1999/012298 WO1999063095A1 (en) 1998-06-04 1999-06-03 Nucleic acid vaccines for prevention of flavivirus infection

Publications (1)

Publication Number Publication Date
BR9910830A true BR9910830A (pt) 2001-02-13

Family

ID=22207979

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9910830-5A BR9910830A (pt) 1998-06-04 1999-06-03 Vacinas de ácido nucléico para prevenção de infecção flavivìrus

Country Status (9)

Country Link
US (3) US7417136B1 (pt)
EP (1) EP1084252B1 (pt)
JP (1) JP4489943B2 (pt)
AU (1) AU778988B2 (pt)
BR (1) BR9910830A (pt)
CA (1) CA2331368C (pt)
DE (1) DE69934583T2 (pt)
IL (2) IL139844A0 (pt)
WO (1) WO1999063095A1 (pt)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9910830A (pt) 1998-06-04 2001-02-13 Us Gov Health & Human Serv Vacinas de ácido nucléico para prevenção de infecção flavivìrus
US7227011B2 (en) 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
US7425437B2 (en) 1999-11-26 2008-09-16 Crucell Holland B.V. Vaccines against West Nile Virus
ES2374131T3 (es) 2000-02-16 2012-02-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Flavivirus quiméricos avirulentos e inmunógenos.
AU2007202304B2 (en) * 2001-04-04 2010-03-18 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, CENTERS FOR DISEASE CONTROL AND PREVENTION Nucleic acid vaccines for prevention of flavivirus infection
KR20090053967A (ko) 2001-07-27 2009-05-28 와이어쓰 웨스트 나일 백신
RU2307872C2 (ru) * 2002-10-09 2007-10-10 СиАйДи КО., ЛТД НОВАЯ ПОЛНОРАЗМЕРНАЯ ГЕНОМНАЯ PHK ВИРУСА ЯПОНСКОГО ЭНЦЕФАЛИТА, ПОЛУЧЕННАЯ ИЗ НЕЕ ИНФЕКЦИОННАЯ кДНК JEV И ИХ ПРИМЕНЕНИЕ
ATE521627T1 (de) 2004-07-27 2011-09-15 Us Gov Health & Human Serv Identifikation kreuzreaktiver epitope des flavivirus-hüllglykoproteins
AU2005318171B2 (en) 2004-12-20 2011-09-29 Crucell Holland B.V. Binding molecules capable of neutralizing West Nile virus and uses thereof
EP1879921B1 (en) 2005-05-12 2011-04-27 Crucell Holland B.V. Host cell specific binding molecules capable of neutralizing viruses and uses thereof
CA3150411C (en) 2009-07-31 2023-09-12 Pnuvax Inc. High yield yellow fever virus strain with increased propagation in cells
US20110182976A1 (en) * 2010-01-28 2011-07-28 National Taiwan Ocean University Lipoplex-patch based dna vaccine
KR20240014580A (ko) 2013-03-15 2024-02-01 다케다 백신즈 인코포레이티드 백신 내의 뎅기 바이러스 키메라 구조체를 위한 조성물 및 방법
CN105311646B (zh) * 2015-05-05 2019-03-29 中国人民解放军第二军医大学 埃兹蛋白在防治乙型脑炎病毒感染中的应用
CN105311647B (zh) * 2015-05-05 2018-11-30 中国人民解放军第二军医大学 丝切蛋白在防治乙型脑炎病毒感染中的应用
EP3468590A1 (en) 2016-06-13 2019-04-17 The United States of America, as represented by the Secretary, Department of Health and Human Services Nucleic acids encoding zika virus-like particles and their use in zika virus vaccines and diagnostic assays
TWI599654B (zh) * 2016-06-24 2017-09-21 國立中興大學 日本腦炎病毒類病毒顆粒表現質體及日本腦炎ｄｎａ疫苗
WO2018052549A1 (en) 2016-09-19 2018-03-22 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
WO2018152526A1 (en) 2017-02-20 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Zika virus vaccines
CN112912106A (zh) 2018-09-05 2021-06-04 武田疫苗股份有限公司 登革热疫苗单位剂量及其施用
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS53133627A (en) 1977-04-25 1978-11-21 Nippon Seibutsu Kagaku Kenkiyu High purity deactivated vaccine for japanese encephalitis
JPH0768267B2 (ja) 1986-06-05 1995-07-26 財団法人阪大微生物病研究会 フラビウイルス抗原
JPS634895A (ja) 1986-06-24 1988-01-09 Mitsubishi Electric Corp オゾン精製水供給装置
JPS6325725A (ja) 1986-07-18 1988-02-03 Nec Corp アドレス表分類方式
JPS63105682A (ja) 1986-10-23 1988-05-10 Mitsubishi Kasei Corp デングウイルス３型由来のｃＤＮＡ
FR2614219B1 (fr) 1987-04-23 1993-07-09 Materiels Annexes Dialyse Procede de fabrication de granules destines a la preparation de solutions de dialyse et installation pour sa mise en oeuvre.
JPH084508B2 (ja) 1987-09-16 1996-01-24 国立予防衛生研究所長 組み換えワクチニアウイルス
US4783502A (en) 1987-12-03 1988-11-08 Ppg Industries, Inc. Stable nonaqueous polyurethane microparticle dispersion
JP2511494B2 (ja) 1988-05-12 1996-06-26 善治 松浦 日本脳炎ウイルス表面抗原蛋白質の製造法
IL91304A0 (en) 1988-08-20 1990-03-19 Us Health Recombinant vaccinia virus for prevention of disease caused by flavivirus
JPH0425408A (ja) 1990-05-21 1992-01-29 Hitachi Ltd ペレタイジングシステムの自動連続運転制御方法
FR2665710A1 (fr) 1990-08-10 1992-02-14 Pasteur Institut Baculovirus recombinant exprimant les proteines e et ns1 de virus appartenant aux flaviviridae ou de virus apparentes aux flaviviridae, applications diagnostiques et therapeutiques.
MY109299A (en) 1990-08-15 1996-12-31 Virogenetics Corp Recombinant pox virus encoding flaviviral structural proteins
US5514375A (en) 1990-08-15 1996-05-07 Virogenetics Corporation Flavivirus recombinant poxvirus vaccine
US5494671A (en) 1990-08-27 1996-02-27 The United States Of America As Represented By The Department Of Health And Human Services C-terminally truncated dengue and Japanese encephalitis virus envelope proteins
EP0872553B1 (en) 1991-09-19 2000-11-15 THE GOVERNMENT OF THE UNITED STATES OF AMERICA as represented by the Secretary of the Department of HEALTH AND HUMAN SERVICES Chimeric and/or growth-restricted flaviviruses
JPH05276941A (ja) * 1992-02-28 1993-10-26 Nippon Zeon Co Ltd フラビウイルス科に属するウイルスの表面抗原タンパク質を含む非感染性の構造物粒子の製造方法
JPH07265093A (ja) 1994-03-30 1995-10-17 Chemo Sero Therapeut Res Inst 哺乳動物細胞を用いる日本脳炎ウイルス表面抗原蛋白質の製法
DE69624815T2 (de) 1995-05-24 2003-07-10 Hawaii Biotech Group Untereinheitsimpfstoff gegen flavivirus infektion
US6136561A (en) 1995-05-24 2000-10-24 Hawaii Biotechnology Group, Inc. Methods of preparing carboxy-terminally truncated recombinant flavivirus envelope glycoproteins employing drosophila melanogaster expression systems
US6074865A (en) 1995-07-20 2000-06-13 The United States Of America As Represented By The Secretary Of The Army Recombinant dengue virus DNA fragment
US6455509B1 (en) * 1996-06-04 2002-09-24 The United States Of America As Represented By The Secretary Of The Navy Dengue nucleic acid vaccines that induce neutralizing antibodies
AU4908197A (en) * 1996-10-18 1998-05-15 Valentis, Inc. Gene expression and delivery systems and uses
ES2244050T3 (es) 1997-02-28 2005-12-01 Acambis Inc. Vacunas quimericas de flavivirus.
AU752191B2 (en) 1997-07-31 2002-09-12 Hawaii Biotech, Inc. Recombinant dimeric envelope vaccine against flaviviral infection
DE69833388D1 (de) * 1997-11-20 2006-04-13 Us Army Medical Res Materiel C Dna impfstoffe gegen zecken-flavivieren
BR9910830A (pt) 1998-06-04 2001-02-13 Us Gov Health & Human Serv Vacinas de ácido nucléico para prevenção de infecção flavivìrus
AU2002305028A1 (en) 2001-02-28 2002-10-28 Brown University Research Foundation West nile virus epitopes and uses thereof
EP1372711A4 (en) 2001-03-12 2005-06-01 Univ Yale COMPOSITIONS AND METHODS OF WEST NIL VIRUS POLYPEPTIDES
JP5276941B2 (ja) 2008-09-24 2013-08-28 株式会社村田製作所 大変位アクチュエータ

Also Published As

Publication number Publication date
US8728488B2 (en) 2014-05-20
DE69934583D1 (de) 2007-02-08
US20120093862A1 (en) 2012-04-19
WO1999063095A1 (en) 1999-12-09
WO1999063095A9 (en) 2000-06-02
JP4489943B2 (ja) 2010-06-23
EP1084252A1 (en) 2001-03-21
DE69934583T2 (de) 2007-10-04
IL139844A0 (en) 2002-02-10
US20080241186A1 (en) 2008-10-02
CA2331368A1 (en) 1999-12-09
EP1084252B1 (en) 2006-12-27
AU778988B2 (en) 2004-12-23
IL139844A (en) 2008-11-03
AU4329699A (en) 1999-12-20
CA2331368C (en) 2009-02-10
US8105609B2 (en) 2012-01-31
US7417136B1 (en) 2008-08-26
JP2002517200A (ja) 2002-06-18

Similar Documents

Publication Publication Date Title
BR9910830A (pt) Vacinas de ácido nucléico para prevenção de infecção flavivìrus
BR0111830A (pt) Método de produção de partìculas semelhantes ao vìrus da influenza (vlps), vlps da influenza, vlps quiméricas, proteìnas da influenza, composições imunogênica e farmacêutica, métodos de imunizar contra a infecção causada pelo vìrus da influenza ou por um microorganismo patogênico outro que não o vìrus da influenza, método de tratamento, e, célula hospedeira transfectada, infectada ou transformada com uma molécula de dna recombinante
BRPI0517773A (pt) composição para cuidados pessoais contendo um derivado de polìmero de galactomanano não-guar
BRPI0309631A8 (pt) vacina tetravalente da dengue contendo uma trivial deleção de 30 nucleotídeos na utr-31&#39; dos tipos de dengue 1,2,3 e 4, ou de vírus antigênicos quiméricos da dengue 1,2,3 e 4
BRPI0010612B8 (pt) vacinas
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
BR9911163A (pt) Formulação de vacina, formulação farmacêutica, vìrus atenuado de influenza, processos para vacinar um indivìduo, para prevenir uma doença infecciosa em um indivìduo, e, para tratar ou prevenir tumores em um indivìduo
DE69818707D1 (de) Chitosan und influenza-antigen(e) enthaltende impfstoff-zubereitungen zur verabreichung durch eine mukosa
EA011652B1 (ru) Терапевтические композиции с нейротоксином ботулина
BRPI0511776A (pt) vìrus atenuado de influenza de suìnos, formulação imunogênica, formulação farmacêutica, métodos para imunizar ou induzir uma resposta imune em um porco, para tratar uma infecção por vìrus de influenza de suìnos em um porco, para tratar cáncer em um porco, e para produzir uma formulação imunogênica, célula, linhagem de células de porco, e, ovo embrionado
BR9810745A (pt) Derivados de benzimidazol
BR0208301A (pt) Vacinas de ácido nucléico para prevenção de infecção por flavivìrus
MXPA02011545A (es) Virus del sindrome respiratorio y reproductor porcino (peesv), vacuna recombinante para el virus de la viruela.
BR0317544A (pt) Uso de uma composição que compreende vlps de hpv 16 e hpv 18, e, métodos para induzir uma resposta imune contra um ou mais do grupo de tipos de hpv oncogênicos, para prevenir infecção e/ou doença causada por um ou mais do grupo de tipos de hpv oncogênicos, para prevenir a infecção de uma população de pacientes por um ou mais tipos de hpv, uso de uma mistura de vlps de hpv 16 e hpv18, e, composição de vacina
BR0109602A (pt) Glóbulos de liberação controlada contendo estavudina
BR112022022859A2 (pt) Vacinas contra sars-cov-2
BR0316291A (pt) Vacina contra hcv, métodos de prevenção ou de tratamento de uma infecção por hcv em um mamìfero e de vacinação de um indivìduo, e, uso de uma vacina contra hcv
WO2022135425A1 (zh) 一种黄病毒属病毒的减毒病毒及其用途
AR054259A1 (es) Vacuna contra virus de papiloma humano (hpv)
NO20051561L (no) Nukleinsyremolekyler som koder for humant papillomavirus og anvendelse av disse i vaksine.
BRPI0916186B1 (pt) vetor de plasmídeo e seu uso, vacina para febre amarela e para vírus de rna infeccioso e vírus atenuado vivo clonalmente purificado homogêneo e seu uso
BR0209251A (pt) Vacina contra vìrus da febre aftosa
Guo et al. Revolutionizing viral disease vaccination: the promising clinical advancements of non-replicating mRNA vaccines
BR0211178A (pt) Cadeias nucleotìdicas quiméricas, proteìnas quiméricas, preparação farmacêutica, e, método diagnóstico
BR0213670A (pt) Composições cosméticas e método para tratamento dos cabelos

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07F Notification of approval that there is no relation to art. 229 of lpi (pipeline patents) [chapter 7.6 patent gazette]

Free format text: NOTIFICACAO DE NAO ANUENCIA RELACIONADA COM O ART. 229 DA LPI

B11D Dismissal acc. art. 38, par 2 of ipl - failure to pay fee after grant in time